• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, June 24, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Drug developer hits major milestone with Lucentis biosimilar

by Myles Hume
May 22, 2020
in Business, Company updates & acquisitions, Local, Macular disease, News, Ophthalmology, Products, Research, Therapeutics, Therapies
Reading Time: 2 mins read
A A
The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.

The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.

Share on FacebookShare on Twitter

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from a Phase 3 clinical trial for its Lucentis biosimilar.

Korean-based Samsung Bioepis has announced that it has met the primary end points in a randomised, double-masked, trial assessing the efficacy, safety and immunogenicity of SB11, a ranibizumab (Lucentis) biosimilar candidate, for neovascular age-related macular degeneration (nAMD).

Compared with Lucentis, which was used as the reference drug, SB11 demonstrated equivalent efficacy in terms of change in best corrected visual activity (BCVA) at week eight and central subfield thickness (CST) at week four.

The results add momentum to the company’s efforts to develop and commercialise two ophthalmology biosimilar candidates, SB11 (ranibizumab/Lucentis) and SB15 (aflibercept/Eylea), in the US, Canada, Europe, Japan, and Australia.

It is aiming to capitalise on the expiration of patents for Lucentis and Eylea – both listed on the Australian Pharmaceutical Benefits Scheme – in the coming years and offer a cheaper alternative for health systems and patients.

In the US alone, it has been estimated that savings generated from biosimilar uptake could reach as high as US$150 billion (AU$217 b) over a 10-year period.

“We are excited to share this news on the development of our first treatment for ophthalmic diseases,” Mr Seongwon Han, medical team leader at Samsung Bioepis, said.

“These 24-week interim results suggest that SB11 will be a valuable treatment option for nAMD, potentially helping millions of patients worldwide.”

Further comparing the SB11 and Lucentis, the trial found the least squares (LS) mean change in BCVA was 6.2 letters for SB11, compared with 7.0 letters for the reference drug Lucentis.

The LS mean change in CST was −108.4μm for SB11 versus −100.1μm for Lucentis. The confidence interval (CI) of the difference between the two treatments in BCVA and CST was within the predefined equivalence margins.

The incidence of treatment-emergent adverse events was 66% for SB11 and 66.9% for Lucentis. The overall incidence of anti-drug antibodies was low (3.0% for SB11 vs 3.1% for Lucentis). Pharmacokinetic serum concentrations also appeared comparable.

In November, Samsung Bioepis announced a new commercialisation agreement with US firm Biogen in a deal worth up to US$310 million (AU$453 m) to supply the biosimilar therapies for major markets, including Australia.

Samsung Bioepis is a joint venture that was established between Samsung BioLogics and Biogen in 2012. It has pipeline of biosimilar candidates for immunology, oncology, ophthalmology and hematology.

Tags: AustraliaBiogenbiosimilarCanadaEuropeEyleaJapanLucentisNovartisPharmaceutical Benefits SchemeranibizumabSamsung BioepisSB11US

Related Posts

The 2025 meeting is taking place in Melbourne 14-17 November. Image: f11photo/stock.adobe.come & Prime Creative Media.

RANZCO has sights on biggest congress yet in 2025

by Staff Writer
June 24, 2025

RANZCO is anticipating its 2025 congress in Melbourne may be one of the largest yet. Since opening registration on 10...

The CureSight device trains the visual system to use both eyes simultaneously, while the user watches any streamed video content of choice through treatment glasses. Image: BOC Instruments.

CureSight – eye-tracking amblyopia treatment for use at home

by Staff Writer
June 24, 2025

BOC Instruments has announced the launch of a new technology that leverages proprietary eye-tracking technology and cloud-based remote monitoring to...

With support from The Fred Hollows Foundation, Chanthoeun from Cambodia received a pair of special prescription glasses to help with her high myopia and she now conducts basic eyesight tests for her children using skills she learned at the vision centre. Image: Michael Amendolia.

Lancet: Glasses still out of reach for millions of people

by Staff Writer
June 24, 2025

New data released in The Lancet Global Health by the Vision Loss Expert Group and World Health Organisation (WHO) and supported by...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited